CA2377339A1 - Utilisation d'hormone de croissance (hgh) pour traiter les troubles de la fonction sexuelle - Google Patents

Utilisation d'hormone de croissance (hgh) pour traiter les troubles de la fonction sexuelle Download PDF

Info

Publication number
CA2377339A1
CA2377339A1 CA002377339A CA2377339A CA2377339A1 CA 2377339 A1 CA2377339 A1 CA 2377339A1 CA 002377339 A CA002377339 A CA 002377339A CA 2377339 A CA2377339 A CA 2377339A CA 2377339 A1 CA2377339 A1 CA 2377339A1
Authority
CA
Canada
Prior art keywords
hgh
substances
growth hormone
therapy
stimulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002377339A
Other languages
English (en)
Inventor
Armin Johannes Becker
Christian Georg Stief
Stefan Uckert
Udo Jonas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Health AB
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2377339A1 publication Critical patent/CA2377339A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH] (Somatotropin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders

Abstract

Utilisation d'hormone de croissance humaine (hGH, GH), seule ou en combinaison avec des principes actifs qui provoquent une stimulation de la GH, qui ont un effet analogue à la GH ou qui favorisent la libération de IGF-I, pour la préparation de médicaments destinés à traiter les troubles de la fonction sexuelle des deux sexes, ainsi que procédé de traitement desdits troubles.
CA002377339A 1999-06-17 2000-06-15 Utilisation d'hormone de croissance (hgh) pour traiter les troubles de la fonction sexuelle Abandoned CA2377339A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19927678.1 1999-06-17
DE19927678 1999-06-17
PCT/EP2000/005517 WO2000078328A2 (fr) 1999-06-17 2000-06-15 UTILISATION D'HORMONE DE CROISSANCE (hGH) POUR TRAITER LES TROUBLES DE LA FONCTION SEXUELLE

Publications (1)

Publication Number Publication Date
CA2377339A1 true CA2377339A1 (fr) 2000-12-28

Family

ID=7911578

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002377339A Abandoned CA2377339A1 (fr) 1999-06-17 2000-06-15 Utilisation d'hormone de croissance (hgh) pour traiter les troubles de la fonction sexuelle

Country Status (6)

Country Link
EP (1) EP1207902A2 (fr)
JP (1) JP2003502379A (fr)
AU (1) AU781842B2 (fr)
CA (1) CA2377339A1 (fr)
NZ (1) NZ516223A (fr)
WO (1) WO2000078328A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2364164A1 (fr) * 2008-11-06 2011-09-14 Kenneth W. Adams Méthode et composition destinées à l amplification de la fonction érectile chez l homme

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7054945B2 (en) * 2001-04-09 2006-05-30 Nokia Corporation Technique for providing announcements in mobile-originated calls
BRPI0511079A (pt) * 2004-05-11 2007-12-26 Emotional Brain Bv usos de uma combinação de um inibidor de pde5 e testosterona ou de um seu análogo, e de testosterona ou de um seu análogo, formulação farmacêutica, e, kit de partes
EP1790343A1 (fr) 2005-11-11 2007-05-30 Emotional Brain B.V. Compositions pharmaceutiques et leur utilisation pour le traitement des dysfonctions sexuelles chez la femme
EP1925307A1 (fr) 2006-11-03 2008-05-28 Emotional Brain B.V. Utilisation de 3-alpha-androstanediol pour le traitement des dysfonctions sexuelles

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5782972A (en) * 1997-03-21 1998-07-21 W.R. Grace & Co.-Conn. Additive for production of highly workable mortar cement
US5916569A (en) * 1997-03-26 1999-06-29 E. Martin Spencer Human erectile dysfunction and methods of treatment

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2364164A1 (fr) * 2008-11-06 2011-09-14 Kenneth W. Adams Méthode et composition destinées à l amplification de la fonction érectile chez l homme
EP2364164A4 (fr) * 2008-11-06 2012-05-02 Kenneth W Adams Méthode et composition destinées à l amplification de la fonction érectile chez l homme

Also Published As

Publication number Publication date
WO2000078328A3 (fr) 2002-02-28
JP2003502379A (ja) 2003-01-21
AU6263500A (en) 2001-01-09
WO2000078328A2 (fr) 2000-12-28
AU781842B2 (en) 2005-06-16
EP1207902A2 (fr) 2002-05-29
NZ516223A (en) 2003-08-29

Similar Documents

Publication Publication Date Title
Shoham et al. Polycystic ovarian syndrome: safety and effectiveness of stepwise and low-dose administration of purified follicle-stimulating hormone
JP3255289B2 (ja) アルファー―２―アドレナリン作動薬及び成長ホルモン放出ペプチドによる肥満症の治療
US6338862B1 (en) Composition and method of use in treating sexual dysfunction using cGMP-specific phosphodiesterase type 5 inhibitors
Darby et al. Treatment of sprue with synthetic L. casei factor (folic acid, vitamin M).
Van de Waal Induction of testicular growth and spermatogenesis by pulsatile, intravenous administration of gonadotrophin‐releasing hormone in patients with hypogonadotrophic hypogonadism
TW577735B (en) Pharmaceutical combined preparation and its use in the treatment of gynaecological disorders
US6809079B2 (en) Compositions and methods for treating female sexual arousal disorder using hydrophobic-calcitonin gene related peptide
JP2002511875A (ja) 勃起機能障害治療用のヨヒンビンおよびアルギニン含有薬
AU781842B2 (en) Use of growth hormone (hGH) for the treatment of sexual functional disturbances
JPH01110630A (ja) 不妊症療法剤
EA009371B1 (ru) Способ управляемой гиперстимуляции яичников и фармацевтический набор для использования в таком способе
US20170087164A1 (en) Method and composition for enhancement of male erectile function
WO2005049053A1 (fr) Composition comprenant un compose de magnesium et/ou un sel de magnesium ameliorant les dysfonctionnements sexuels
Bierich Therapy with growth hormone–old and new indications
Lundberg Blood levels of FSH, LH, TSH, and GH in parkinsonian patients before and during L‐dopa treatment
US10300101B2 (en) Methods and compositions for enhancing or maintaining fertility
Wakerlin Kidney and hypertension
CA2325930A1 (fr) Medicament pour prevenir et traiter la dysfonction sexuelle
Hammond et al. Diagnostic and therapeutic uses of gonadotropin-releasing hormone
DuÈndar et al. The effect of estrogen-replacement therapy on clitoral-cavernosal tissue in oophorectomized rats: a histo-quantitative study by image analyzer
JPH01501708A (ja) アミノ酸の経鼻投与
Leung et al. Neuroendocrine complications of cancer therapy
JPH04506969A (ja) 成人男性における不妊症又は生殖能力低下の治療方法および該方法のための製剤の使用
Biasioli et al. Hyperprolactinemia as a marker of neurotransmitter imbalance in uremic population
Hung The Role of Endogenous Opioids in Pregnancy and Anesthesia

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead